Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(63)

カスタマーフィードバック(14)

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M4rCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwME[xJO69VQ>? NEH3NXFUSU6JRWK=
ALL-PO M4PZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PSNGlEPTB;MD6wOlM2PSEQvF2= M2jCSnNCVkeHUh?=
697 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEm5O|Yh|ryP NV\oRpRqW0GQR1XS
NCI-H748 M12yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKNHNIUUN3ME2wMlExOzN2IN88US=> NX3lVWhrW0GQR1XS
NKM-1 NHjz[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFb2lEPTB;MD6xNFkyOiEQvF2= NH;ZcohUSU6JRWK=
ES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUGyOVUh|ryP Mo\oV2FPT0WU
NCI-H1963 M2PtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUG1O|kh|ryP MUDTRW5ITVJ?
NCI-H1417 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITOZoVKSzVyPUCuNVI6PzRizszN M1;icnNCVkeHUh?=
NEC8 M2\EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7YTWM2OD1yLkGzOVI4KM7:TR?= M3\lOHNCVkeHUh?=
CRO-AP2 NGHqXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTHTWM2OD1yLkG2PFg6KM7:TR?= NWLsfohEW0GQR1XS
A3-KAW NHL4SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUe2Nlch|ryP MVzTRW5ITVJ?
SF539 NFGyVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPlTWM2OD1yLkG5OVk{KM7:TR?= NHvydWhUSU6JRWK=
NOS-1 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j2V2lEPTB;MD6xPVYyQSEQvF2= MWXTRW5ITVJ?
NTERA-S-cl-D1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTpTWM2OD1yLkKwNVE{KM7:TR?= M2KydHNCVkeHUh?=
COR-L88 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT2TWM2OD1yLkKyPVU6KM7:TR?= M33mfHNCVkeHUh?=
EM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPRTWM2OD1yLkK0NFc6KM7:TR?= NUX0eFhsW0GQR1XS
KARPAS-45 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;iUppKSzVyPUCuNlc5OzNizszN M13hPXNCVkeHUh?=
DSH1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTJcZJ5UUN3ME2wMlI5PzB6IN88US=> Mn62V2FPT0WU
HT-144 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwM{CyOVYh|ryP MVvTRW5ITVJ?
ATN-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfYXFk3UUN3ME2wMlMxPTd4IN88US=> MYTTRW5ITVJ?
HEL NWPVWnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXTTWM2OD1yLkOxN|Q5KM7:TR?= M4HvVXNCVkeHUh?=
NB12 M{nicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{G3OVYh|ryP MXfTRW5ITVJ?
LU-139 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XoPWlEPTB;MD6zN|UyKM7:TR?= NWm3TYFlW0GQR1XS
J-RT3-T3-5 NY\3ZmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwM{O3NVYh|ryP NGnuemhUSU6JRWK=
MOLT-13 NWrheGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrQ[3NKSzVyPUCuN|M5OSEQvF2= NV7MepZKW0GQR1XS
SR M{LGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITtdZZKSzVyPUCuN|QzPjFizszN NXjXU3dzW0GQR1XS
CMK M135U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwM{W3Nlch|ryP MWLTRW5ITVJ?
ES8 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTTWM2OD1yLkO2NFIzKM7:TR?= MXzTRW5ITVJ?
LB647-SCLC NFnYPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPY[GJKSzVyPUCuN|Y4OyEQvF2= MWrTRW5ITVJ?
TE-8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwM{[5N|Uh|ryP M2PTZXNCVkeHUh?=
BV-173 NI\yPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwM{exNlEh|ryP M1XjVnNCVkeHUh?=
DEL NEXHfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7oTWM2OD1yLkO3OFg4KM7:TR?= NX3UWIVZW0GQR1XS
ARH-77 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HscGlEPTB;MD6zPFE6OyEQvF2= MV7TRW5ITVJ?
NCCIT MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXhZ25KSzVyPUCuN|g3PDlizszN NXj4N|Z[W0GQR1XS
RPMI-8402 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD1yLkO4O|AyKM7:TR?= NHjmbpBUSU6JRWK=
MONO-MAC-6 NW\vSYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe0TWVKSzVyPUCuN|g4PzZizszN M4\wVXNCVkeHUh?=
SK-MM-2 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnnZnJKSzVyPUCuN|k5PjhizszN Mk[zV2FPT0WU
CHP-126 M{XTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrkSnlpUUN3ME2wMlQxOjNzIN88US=> MlvlV2FPT0WU
A101D NEfoe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNECzJO69VQ>? NH;5cmdUSU6JRWK=
SCH NIrES2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrGVYpKSzVyPUCuOFA{PDJizszN M{\zbHNCVkeHUh?=
NMC-G1 NV\BPFZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNECzOlch|ryP NVjUdnR{W0GQR1XS
NCI-H209 NHnnfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ITWM2OD1yLkSwOlE{KM7:TR?= NH3HOGxUSU6JRWK=
MOLT-16 NVHmOY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETtRllKSzVyPUCuOFExOTdizszN MWTTRW5ITVJ?
RPMI-6666 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PNdmlEPTB;MD60NVEzKM7:TR?= NVz5cI5zW0GQR1XS
OPM-2 NXL0R5dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H4ZmlEPTB;MD60NVUyOyEQvF2= MX;TRW5ITVJ?
MRK-nu-1 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3PTWM2OD1yLkSzNVU{KM7:TR?= MU\TRW5ITVJ?
BC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD1yLkSzOFA{KM7:TR?= MYTTRW5ITVJ?
MHH-NB-11 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNEO0OVMh|ryP MoHzV2FPT0WU
Ramos-2G6-4C10 NUjkUG5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5RWlEPTB;MD60N|g6PyEQvF2= NXzkV3N6W0GQR1XS
LS-513 NF\QWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHUTWM2OD1yLkS0OVAyKM7:TR?= MYrTRW5ITVJ?
K5 NEDHSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHDTWM2OD1yLkS3NFI2KM7:TR?= MlHNV2FPT0WU
HOP-62 NGTJU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvRSWZ3UUN3ME2wMlQ5OzV6IN88US=> MlPPV2FPT0WU
NCI-H187 M3TvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i1fmlEPTB;MD60PVIzPyEQvF2= NEPNc3pUSU6JRWK=
BE-13 M{nwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fuRWlEPTB;MD60PVY3OSEQvF2= NWTQco5tW0GQR1XS
HC-1 NYHNeXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDIdJRyUUN3ME2wMlUxPDd|IN88US=> M17lSnNCVkeHUh?=
ACN NHHvWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDFeHVKSzVyPUCuOVExOjhizszN M4HVZnNCVkeHUh?=
HCC1599 NEPwUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jTbGlEPTB;MD61NVU4KM7:TR?= NIHjXWlUSU6JRWK=
MV-4-11 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPXTWM2OD1yLkWzNFQyKM7:TR?= Mm\pV2FPT0WU
LC-2-ad MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNUO2OlMh|ryP M3LabXNCVkeHUh?=
HL-60 M1y5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD1yLkW0NlYyKM7:TR?= NIT1cmJUSU6JRWK=
NB17 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNUSzPEDPxE1? NUTUdo8{W0GQR1XS
TE-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6UJI1UUN3ME2wMlU2OzB4IN88US=> NV7rS|RoW0GQR1XS
NCI-H524 NFXBXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT4bYRvUUN3ME2wMlU2PDBzIN88US=> MVvTRW5ITVJ?
MZ7-mel M1\XWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKwV2lpUUN3ME2wMlU3OTB3IN88US=> MnTGV2FPT0WU
L-363 M2jC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvCUGVKSzVyPUCuOVY3PTdizszN M3fs[XNCVkeHUh?=
BL-41 M2rMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNU[4PFkh|ryP NF3B[45USU6JRWK=
LU-134-A M1LM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULPTmFFUUN3ME2wMlU4ODd|IN88US=> Ml[zV2FPT0WU
SIG-M5 M4XWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNUe4OFgh|ryP NF;CO5dUSU6JRWK=
ONS-76 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi4TWM2OD1yLkW4NlQzKM7:TR?= M1vPenNCVkeHUh?=
KARPAS-299 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\3bZo2UUN3ME2wMlU5PTB2IN88US=> NVjVfY0xW0GQR1XS
DU-4475 NXzROVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFTWM2OD1yLkW4O|A{KM7:TR?= MYLTRW5ITVJ?
NB69 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfhTWM2OD1yLkW5PFI2KM7:TR?= NFPYRmNUSU6JRWK=
MHH-PREB-1 NX3DPVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP2SIhKSzVyPUCuOlA4OTlizszN NH3QepdUSU6JRWK=
LU-165 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PZbmlEPTB;MD62NVgyOiEQvF2= NXH5cYtYW0GQR1XS
LOUCY MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjhTYp{UUN3ME2wMlY{OzZ2IN88US=> M2P3cXNCVkeHUh?=
NCI-H526 NFSzVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUizV4RLUUN3ME2wMlY{PTRzIN88US=> MVfTRW5ITVJ?
KE-37 M3OxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLoRZRPUUN3ME2wMlY1Ojd4IN88US=> MkDzV2FPT0WU
NALM-6 M33KRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;QTWM2OD1yLk[0PFYh|ryP MYnTRW5ITVJ?
CW-2 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTZWlEPTB;MD62OVc6PCEQvF2= MkmxV2FPT0WU
SU-DHL-1 M{L6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNkW5OFch|ryP NUT2cZA1W0GQR1XS
NB13 M{iySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNk[4NVch|ryP M1\x[XNCVkeHUh?=
QIMR-WIL NUPw[Hp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNkizOFMh|ryP MWHTRW5ITVJ?
ECC12 NFzYcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwN{CwPFYh|ryP NH;teZlUSU6JRWK=
KALS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknnTWM2OD1yLkewOFkzKM7:TR?= MX\TRW5ITVJ?
COR-L279 M1H6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkOm1KSzVyPUCuO|A6QTZizszN MmHKV2FPT0WU
NB14 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLETWM2OD1yLkeyOlE4KM7:TR?= M3f0e3NCVkeHUh?=
CCRF-CEM MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj0TWM2OD1yLke0OlYyKM7:TR?= MXjTRW5ITVJ?
SW954 NUPPSFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD1yLke1PVk6KM7:TR?= MkjKV2FPT0WU
IST-SL1 NV;vdHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hp[mlEPTB;MD63O|M1QCEQvF2= MUfTRW5ITVJ?
LAMA-84 NIXTbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[zb2h1UUN3ME2wMlc4PTZ5IN88US=> NUTZ[4pHW0GQR1XS
Daudi NFXwRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P2XWlEPTB;MD63O|Y5OSEQvF2= M3vIUnNCVkeHUh?=
BC-3 NULreodqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwN{izNFgh|ryP M4TQfnNCVkeHUh?=
HCC2998 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPUbldKSzVyPUCuO|g{PiEQvF2= NYXidG9EW0GQR1XS
NCI-H69 NEjLfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLVO4dOUUN3ME2wMlgxOTR5IN88US=> MWLTRW5ITVJ?
CPC-N NUjpd5k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHkPItHUUN3ME2wMlgxPTJ2IN88US=> MYLTRW5ITVJ?
NOMO-1 NGfid4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDUTGxKSzVyPUCuPFExQDRizszN NIOwVYRUSU6JRWK=
CESS M3\NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjwTWM2OD1yLkixNVk4KM7:TR?= NWjnbop6W0GQR1XS
LC4-1 NXHGUGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfrTWM2OD1yLki0NFA4KM7:TR?= MVzTRW5ITVJ?
BL-70 NH3CU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3TWM2OD1yLki1O|AzKM7:TR?= MoDSV2FPT0WU
ES4 NXHGO|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPZS2lyUUN3ME2wMlg2QDZ6IN88US=> NYjQeZVwW0GQR1XS
HCE-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHixbGZKSzVyPUCuPFcyPzFizszN MYfTRW5ITVJ?
JAR M3:ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;BWGlEPTB;MD64O|gzPyEQvF2= M1W3fXNCVkeHUh?=
ST486 NHXPflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfJTWM2OD1yLki3PVE4KM7:TR?= MmfmV2FPT0WU
KS-1 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tp[WlEPTB;MD64PFA6PiEQvF2= M2fkWHNCVkeHUh?=
GDM-1 NWTjTJV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwOEi2PFch|ryP MWXTRW5ITVJ?
EHEB M2\SSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOUK1PFUh|ryP NUfwNXdSW0GQR1XS
LB2518-MEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLLPFdKSzVyPUCuPVMzQDRizszN M3zFRnNCVkeHUh?=
GOTO NGfhN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\RXoE{UUN3ME2wMlk2ODd4IN88US=> M4\kPHNCVkeHUh?=
LXF-289 NEHK[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHK[lltUUN3ME2wMlk2QTBzIN88US=> MV;TRW5ITVJ?
ES6 M1vsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33SSmlEPTB;MD65OlQ{PyEQvF2= NHjXXFJUSU6JRWK=
OS-RC-2 NHTCbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjKTWlKSzVyPUCuPVY5OyEQvF2= M1vzTHNCVkeHUh?=
DMS-153 NEPiUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXGbWtwUUN3ME2wMlk4PDZ7IN88US=> M1znOXNCVkeHUh?=
SK-PN-DW NFPsPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPb2lEPTB;MD65O|g{OSEQvF2= MVfTRW5ITVJ?
HH NWPDS2I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOUi5OVkh|ryP M2WyWnNCVkeHUh?=
SH-4 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTmemFjUUN3ME2xMlAzPDFizszN Ml24V2FPT0WU
MOLT-4 NV3mXmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvaVItXUUN3ME2xMlA{PDV2IN88US=> M4nJbXNCVkeHUh?=
TGW NXntbWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfjeXVmUUN3ME2xMlA4Pjd3IN88US=> MV\TRW5ITVJ?
L-540 NYWweGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfwNJBKSzVyPUGuNVA3ODRizszN NVnId5ZLW0GQR1XS
PF-382 M{\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LSbGlEPTB;MT6xNVUyOyEQvF2= M324fnNCVkeHUh?=
LC-1F NXjxVIluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMbGlEPTB;MT6xNlAxPyEQvF2= NXzrboE3W0GQR1XS
OVCAR-4 M1LNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml34TWM2OD1zLkGzNVY2KM7:TR?= MkGwV2FPT0WU
A4-Fuk NGDqSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf5ToFTUUN3ME2xMlE2OzZ2IN88US=> MXnTRW5ITVJ?
HCC2218 M{D6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3vdnNKSzVyPUGuNVY3PDFizszN MmnJV2FPT0WU
HAL-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe5NlNHUUN3ME2xMlE3QTR|IN88US=> MXrTRW5ITVJ?
IST-MEL1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1zLkG3OlU6KM7:TR?= MWfTRW5ITVJ?
NCI-H719 NFP6clFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTwNXpEUUN3ME2xMlE4QDl6IN88US=> NHTvbHVUSU6JRWK=
EVSA-T MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYezepJlUUN3ME2xMlE5OTF2IN88US=> MknwV2FPT0WU
SK-NEP-1 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[2ZZNKSzVyPUGuNlAzPjZizszN NFzNfVFUSU6JRWK=
OCUB-M NWX0UXZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv3cJRUUUN3ME2xMlIyPDh7IN88US=> NFTLTohUSU6JRWK=
MEG-01 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXMfHBKSzVyPUGuNlIyOThizszN M3ryPHNCVkeHUh?=
no-10 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWTWM2OD1zLkKzNVEzKM7:TR?= MWnTRW5ITVJ?
MHH-CALL-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLjRnVKSzVyPUGuNlQ4OjFizszN NGCwWVdUSU6JRWK=
SK-N-DZ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMkS3O|Yh|ryP NEXKcYlUSU6JRWK=
SCLC-21H MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[0TWM2OD1zLkK2OFc5KM7:TR?= NVvGVpNCW0GQR1XS
CTV-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\BPVBPUUN3ME2xMlI4PDJ3IN88US=> M4fTVnNCVkeHUh?=
NB1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq5Tm1KSzVyPUGuNlc4OzJizszN M{H4R3NCVkeHUh?=
NCI-H64 NHe0cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMki0OlIh|ryP MUPTRW5ITVJ?
MDA-MB-134-VI MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjlSW1PUUN3ME2xMlI5PTd5IN88US=> MoDPV2FPT0WU
LB2241-RCC MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X4ZWlEPTB;MT6yPFY3OyEQvF2= MWjTRW5ITVJ?
8-MG-BA NFnkWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPRTWM2OD1zLkK4PFY3KM7:TR?= NFrJTFNUSU6JRWK=
LP-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi3NlhEUUN3ME2xMlI6QTR5IN88US=> M{nQTHNCVkeHUh?=
LS-411N NWq3Z|BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDdmdKSzVyPUGuN|A6QThizszN NILie|BUSU6JRWK=
CAL-148 NEfiN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLlTWM2OD1zLkOyOVQzKM7:TR?= NXfPZ4pQW0GQR1XS
NCI-H2171 NF6x[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LOO2lEPTB;MT6zOFUxOiEQvF2= MoH2V2FPT0WU
JiyoyeP-2003 NYni[JFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PkNGlEPTB;MT6zOVM6KM7:TR?= MnLFV2FPT0WU
NCI-H2107 M3O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX1TWM2OD1zLkO1PFg{KM7:TR?= MoXxV2FPT0WU
BB30-HNC NGPl[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPR5JjUUN3ME2xMlM5QTd6IN88US=> M2PUUnNCVkeHUh?=
K-562 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW3bXlKSzVyPUGuN|kzOTlizszN M3W0dnNCVkeHUh?=
PSN1 NU[yUWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X0bWlEPTB;MT60NlI5PyEQvF2= M{DZZnNCVkeHUh?=
HCC2157 NFHuPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1zLkSyOlkyKM7:TR?= NVHzeZp3W0GQR1XS
SBC-1 M2PNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK4[WhKSzVyPUGuOFI4PDFizszN MXrTRW5ITVJ?
MC116 NXW2XGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnMNGdmUUN3ME2xMlQ{PjF3IN88US=> M2TJfXNCVkeHUh?=
KARPAS-422 NI\1WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDzNYhKSzVyPUGuOFU{PThizszN NFfyfodUSU6JRWK=
LB996-RCC MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGzWY1KSzVyPUGuOFcyODNizszN MULTRW5ITVJ?
MSTO-211H NGXRPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLF[5VsUUN3ME2xMlQ4QTh5IN88US=> MV\TRW5ITVJ?
BT-474 NEW2NHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWwUYZOUUN3ME2xMlUyPzZ2IN88US=> MofTV2FPT0WU
A388 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNUG5OFUh|ryP NUPmTXY3W0GQR1XS
SJSA-1 NH3TVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\TSWlEPTB;MT61NlI3KM7:TR?= MVnTRW5ITVJ?
COLO-829 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPW[YRnUUN3ME2xMlU{PTZ2IN88US=> NH7uR49USU6JRWK=
KM-H2 NUDJfmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTXO|d6UUN3ME2xMlU3PjdizszN M3ftSHNCVkeHUh?=
GR-ST Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwNU[4NkDPxE1? MWPTRW5ITVJ?
RPMI-8866 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNkCxOFQh|ryP NGj3e2VUSU6JRWK=
KG-1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTQb5NKSzVyPUGuOlE6ODFizszN MVvTRW5ITVJ?
NCI-H82 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PtXmlEPTB;MT62N|QxPiEQvF2= MYLTRW5ITVJ?
LB1047-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7RO5hKSzVyPUGuOlM1PTlizszN NXHodGZ{W0GQR1XS
KM12 NVjaXGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwNkS3JO69VQ>? NHLO[FlUSU6JRWK=
NB5 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HuUGlEPTB;MT62OVY4PyEQvF2= MlzFV2FPT0WU
HDLM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W1TGlEPTB;MT62PFI5OSEQvF2= Mn;XV2FPT0WU
KU812 NXLURZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn0TWM2OD1zLk[5OlA2KM7:TR?= MknlV2FPT0WU
DB NWLFSpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTERYlKSzVyPUGuO|A{PTNizszN MXXTRW5ITVJ?
HD-MY-Z NFKzZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq4Z4tZUUN3ME2xMlc2OjN2IN88US=> M3fM[HNCVkeHUh?=
KURAMOCHI MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwN{eyNFch|ryP MXvTRW5ITVJ?
ETK-1 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jBOmlEPTB;MT63PFg4QSEQvF2= M{DzPHNCVkeHUh?=
SK-UT-1 M3X5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfyWYFKSzVyPUGuO|k{QDhizszN M3HuWXNCVkeHUh?=
HUTU-80 M1HWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\BNoRzUUN3ME2xMlc6PTB6IN88US=> MX3TRW5ITVJ?
ES7 M13FS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTK[FJKSzVyPUGuPFA{ODJizszN MWfTRW5ITVJ?
SW872 M2nlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DQNGlEPTB;MT64NVM6PSEQvF2= NGXFR2NUSU6JRWK=
TK10 NYjIZZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkntTWM2OD1zLkizNVA5KM7:TR?= M{jqOHNCVkeHUh?=
LB831-BLC M4izNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNSnFSUUN3ME2xMlg{PTZ|IN88US=> M{\UcHNCVkeHUh?=
TE-9 M1:3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn2RXFTUUN3ME2xMlg1PDJ{IN88US=> NF;Tdm5USU6JRWK=
MLMA NIj6ZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnyTWM2OD1zLki4NlM1KM7:TR?= MV3TRW5ITVJ?
D-542MG Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PKSWlEPTB;MT64PVM4OyEQvF2= NWTuc4NJW0GQR1XS
EW-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jmfWlEPTB;MT65NlczKM7:TR?= MXrTRW5ITVJ?
LOXIMVI NYXqUoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nqNGlEPTB;MT65N|I5KM7:TR?= NIjFT5dUSU6JRWK=
GB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;5NmlEPTB;MT65N|g3PiEQvF2= NXLNOnZNW0GQR1XS
IST-SL2 NX7mZm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwMECyOlIh|ryP M1:2PHNCVkeHUh?=
LAN-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTKbIhUUUN3ME2yMlAyQTZ4IN88US=> NFfxV4JUSU6JRWK=
NCI-H510A NF60bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fKdmlEPTB;Mj6wOFUxOiEQvF2= NIr5V4FUSU6JRWK=
NCI-H1092 NFfhVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwMEWxNlQh|ryP MV;TRW5ITVJ?
HT NID4SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwMUC0OVQh|ryP NXrJPJVRW0GQR1XS
RL95-2 M2\Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFznZmpKSzVyPUKuNVE1QDJizszN MnLWV2FPT0WU
NCI-H1355 NUD6VZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfZTWM2OD1{LkGxO|kzKM7:TR?= MUHTRW5ITVJ?
NCI-H720 NXPPdZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXPO5NpUUN3ME2yMlE3QDd|IN88US=> MoqzV2FPT0WU
NCI-H1522 M3fK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDlO2RKSzVyPUKuNlE4OjNizszN M2D6R3NCVkeHUh?=
LB373-MEL-D NULIN5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXviSJZPUUN3ME2yMlI3QTB{IN88US=> NWC0SJhIW0GQR1XS
DG-75 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtfGVKSzVyPUKuNlcyPDhizszN M1\1[nNCVkeHUh?=
ML-2 NWnDS3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rR[GlEPTB;Mj6zNlg2PSEQvF2= MlvDV2FPT0WU
SF126 M1vhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XIXmlEPTB;Mj6zN|A6PCEQvF2= NGjNXXZUSU6JRWK=
MPP-89 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XU[GlEPTB;Mj6zN|E1PSEQvF2= Mm[zV2FPT0WU
NCI-H345 M1\RTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwM{OyO|ch|ryP NET1[lJUSU6JRWK=
LS-123 M4Tsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K0SmlEPTB;Mj6zOFk{PiEQvF2= NVGyW3BWW0GQR1XS
NB10 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XLWWlEPTB;Mj60NVA6OiEQvF2= NGPiNYxUSU6JRWK=
CGTH-W-1 M3LDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrDR|hnUUN3ME2yMlQzOjZ5IN88US=> MWDTRW5ITVJ?
CP66-MEL NX3tOZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEntbHpKSzVyPUKuOFc4PyEQvF2= M3XsZnNCVkeHUh?=
L-428 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDwO|Q2UUN3ME2yMlQ5PTJzIN88US=> NFfqVVlUSU6JRWK=
DMS-79 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe1eI9KSzVyPUKuOVQyODNizszN MUPTRW5ITVJ?
NCI-H1882 NUCwZmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjYNZVXUUN3ME2yMlY4PTZ{IN88US=> MmHWV2FPT0WU
KGN NFzxc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLM[mlKSzVyPUKuO|Y5PzZizszN NVrJcWVQW0GQR1XS
EW-1 NH\KTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jwfWlEPTB;Mj63O|A5OyEQvF2= NG\TO3dUSU6JRWK=
U-266 M3KxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofzTWM2OD1{Lki0PFI{KM7:TR?= MYXTRW5ITVJ?
COLO-320-HSR MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DWeWlEPTB;Mj64OVY1OSEQvF2= MXrTRW5ITVJ?
KMOE-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zXWmlEPTB;Mj64O|cyOSEQvF2= NIPjSVZUSU6JRWK=
BB49-HNC NV3pe2NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwOUK0PEDPxE1? NGrhUYpUSU6JRWK=
GI-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETnNo5KSzVyPUKuPVI6PTdizszN MofWV2FPT0WU
NCI-H1304 NEC4NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr6V|RKSzVyPUOuNFA2OTFizszN MWnTRW5ITVJ?
NCI-H2227 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwMEKwO|kh|ryP M1jyUHNCVkeHUh?=
U-87-MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K5[GlEPTB;Mz6wN|UyOyEQvF2= NWLBbJl3W0GQR1XS
NCI-H747 NUjlOXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDlNHBpUUN3ME2zMlA2OjB4IN88US=> MnzEV2FPT0WU
CTB-1 M4\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\DPZhCUUN3ME2zMlA2Ozd4IN88US=> MYnTRW5ITVJ?
RPMI-8226 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWwTWM2OD1|LkG0N|c5KM7:TR?= MkL3V2FPT0WU
NCI-H2141 M1zJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMU[1OlYh|ryP NIrCSWJUSU6JRWK=
IST-MES1 NGfqemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHWbWRKSzVyPUOuNVgzPzlizszN MUTTRW5ITVJ?
TE-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjKW|FKSzVyPUOuNlE{PDJizszN MliyV2FPT0WU
UACC-257 NVHsTXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmO2lEPTB;Mz60N|Y2QSEQvF2= Mny4V2FPT0WU
SK-N-FI NHfN[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7q[YxbUUN3ME2zMlQ2OjJ5IN88US=> NULxVXJoW0GQR1XS
MFH-ino NV[zSVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNwNE[1PFkh|ryP MWfTRW5ITVJ?
SF268 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwNEixO|Qh|ryP MXvTRW5ITVJ?
TE-12 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Lob2lEPTB;Mz61NVY6QSEQvF2= M{nGWnNCVkeHUh?=
NB6 M{\NXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r2T2lEPTB;Mz61OVU3OyEQvF2= MWXTRW5ITVJ?
DJM-1 M2TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3t[XBKSzVyPUOuOVk5QTlizszN NEDJRmdUSU6JRWK=
MZ1-PC MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwNkG2NlQh|ryP NUjkOWRVW0GQR1XS
OCI-AML2 M1zBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HwfWlEPTB;Mz62NlY4OSEQvF2= MmDwV2FPT0WU
NCI-H1155 NIOzVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fUVWlEPTB;Mz63NFk1PyEQvF2= MXvTRW5ITVJ?
RKO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWTmlEPTB;Mz63O|E5QSEQvF2= MnfmV2FPT0WU
ECC4 NEfjVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwOUexPVUh|ryP NVjvb3F7W0GQR1XS
BB65-RCC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwOUe1OFch|ryP NYO3dZhiW0GQR1XS
EB-3 NUTkfHY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwOUm2N|Mh|ryP NGTtWI1USU6JRWK=
SHP-77 M1\3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTRwMEC1NlQh|ryP MnLCV2FPT0WU
NCI-H2196 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XhVGlEPTB;ND6wOVYzPSEQvF2= NYPSUnJtW0GQR1XS
GI-ME-N NVnwXpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD12LkC2N|k6KM7:TR?= NWLYc|dqW0GQR1XS
MN-60 NIjTUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3bGlEPTB;ND6xNFg4KM7:TR?= NXTX[oJPW0GQR1XS
NCI-H1694 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwMUO0NFUh|ryP MnvQV2FPT0WU
LU-65 NIDoZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXU[W1JUUN3ME20MlE2OzN{IN88US=> NHTQc4hUSU6JRWK=
NCI-H1436 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwMUizN|Mh|ryP MmqzV2FPT0WU
KINGS-1 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1b45KSzVyPUSuN|E1OzJizszN NWfSR|B2W0GQR1XS
GT3TKB MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne4TWM2OD12LkOzNlY5KM7:TR?= MlGwV2FPT0WU
Becker M1;QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;pTWM2OD12LkO3N|EzKM7:TR?= NGS2ZnFUSU6JRWK=
HCC1187 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrtXXJqUUN3ME20Mlg6PjV5IN88US=> MmLQV2FPT0WU
D-502MG NXvsRVBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXNSmJKSzVyPUWuNFA1OTZizszN M{WydHNCVkeHUh?=
VA-ES-BJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLPIlYUUN3ME21MlE{Pzd6IN88US=> NWPjPYg2W0GQR1XS
NB7 NGr4ZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXiTWM2OD13LkG0NVEzKM7:TR?= MkTTV2FPT0WU
SW962 NYPYZmg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:xdJVKSzVyPUWuN|g5OTRizszN NUXqbWY3W0GQR1XS
no-11 NHnEVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwN{[zOFMh|ryP NXrJU48xW0GQR1XS
KNS-81-FD M{HHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;tTWM2OD13LkmwOlk1KM7:TR?= NETBb|VUSU6JRWK=
COLO-684 M1;TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVwOUm0PVQh|ryP NFvLVnpUSU6JRWK=
D-263MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e0b2lEPTB;Nj6wPFg6PSEQvF2= MnvvV2FPT0WU
EW-24 NVfSXmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXMSJU4UUN3ME22MlI5PTFizszN M4PwdnNCVkeHUh?=
TE-10 NE\lTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPHOHdKSzVyPU[uOFI3OjNizszN NITuT29USU6JRWK=
EKVX NHzEXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwNE[zNlEh|ryP MWrTRW5ITVJ?
NCI-H1648 M2\rSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWx[4F7UUN3ME22MlY4PTV5IN88US=> MnntV2FPT0WU
LB771-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ETWM2OD14LkmyN|AyKM7:TR?= M1r0NHNCVkeHUh?=
SK-MEL-1 NGrBV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGwTWM2OD16LkGzNVY3KM7:TR?= MU\TRW5ITVJ?
COLO-668 NH7wW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD2TWM2OD16LkK3O|g3KM7:TR?= NWDuUGpMW0GQR1XS
EW-12 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXqTWM2OD16LkSwPFA{KM7:TR?= NIXJVJpUSU6JRWK=
A253 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRThwOES2OlEh|ryP NWDqR5FNW0GQR1XS
NCI-H2126 NIXyS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzqRoFKSzVyPUiuPFk{OTlizszN MV3TRW5ITVJ?
Calu-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Syc2lEPTB;OD65PVA1OiEQvF2= MlTMV2FPT0WU
NCI-H23 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke5TWM2OD17LkG3O|Q3KM7:TR?= M{GySXNCVkeHUh?=
WSU-NHL NF3GcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGUYpKSzVyPUmuO|c1PzhizszN NF74[4FUSU6JRWK=
MMAC-SF MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MornTWM2OD17Lkm3PVA1KM7:TR?= MX\TRW5ITVJ?
SK-LMS-1 NYDUWphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7C[JV4UUN3ME2xNE4zQDN2IN88US=> NGjpbXdUSU6JRWK=
GCIY MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKdoZKSzVyPUGwMlU6OjRizszN NXy5TWZHW0GQR1XS
TE-15 NYXteGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DPTGlEPTB;MUGuOlAxPCEQvF2= NY\Bd5dPW0GQR1XS
EoL-1-cell MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M136eWlEPTB;MUGuO|Y5OiEQvF2= M3r2fXNCVkeHUh?=
NCI-H2081 NV\kVmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLke3PFYh|ryP NVfHd3lXW0GQR1XS
EW-3 NXi4NHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzobFBKSzVyPUGyMlI1PjNizszN MnLaV2FPT0WU
CAS-1 NXLGemU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF{LkO2N|Eh|ryP MX;TRW5ITVJ?
C2BBe1 NFfq[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2yOoI3UUN3ME2xNk43OTNzIN88US=> M3PNVHNCVkeHUh?=
D-247MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1eWlEPTB;MUKuO|k2OiEQvF2= MWXTRW5ITVJ?
NCI-SNU-5 NV;EUY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHsOXdKSzVyPUGyMlgxOTNizszN Ml\YV2FPT0WU
LS-1034 M3LFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5XYVKSzVyPUG0MlM6PzVizszN NV;qVYJqW0GQR1XS
EW-18 NIXKOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLc2lEPTB;MUSuOFQ5KM7:TR?= NV\Kb5hIW0GQR1XS
Raji MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaepliUUN3ME2xOE42ODR7IN88US=> NIDkO|lUSU6JRWK=
D-283MED NX3ISGRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfS[IZKSzVyPUG0MlYzPzFizszN NFjyfJZUSU6JRWK=
MZ2-MEL MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr3Z2dKSzVyPUG0Mlk3QTZizszN MnHiV2FPT0WU
NCI-SNU-16 NUXDd5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF3LkS2N|Mh|ryP M2OzfnNCVkeHUh?=
P30-OHK MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX6cIhKSzVyPUG3Mlc5OzFizszN M3i5fHNCVkeHUh?=
RXF393 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xZY9KSzVyPUG5MlAyQDZizszN NVPq[FFKW0GQR1XS
NCI-H1395 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLOcHh2UUN3ME2yNE43PzB|IN88US=> NGPwZVZUSU6JRWK=
U-698-M NUDUblBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPPTIZ2UUN3ME2yNE44ODd3IN88US=> M3n4b3NCVkeHUh?=
NCI-SNU-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvDTWM2OD1{MD63NlI{KM7:TR?= NHy5bWdUSU6JRWK=
SW684 M4DPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiy[oVKSzVyPUKxMlE4OTZizszN NWW5dYFXW0GQR1XS
NCI-H716 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJzLkOxOVQh|ryP MX\TRW5ITVJ?
JVM-2 NWDHTHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLKVYI{UUN3ME2yNU41OTN|IN88US=> M{\lS3NCVkeHUh?=
NCI-H1581 NV\tN|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXnS3pKSzVyPUKyMlQyPDhizszN MWTTRW5ITVJ?
CA46 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLTPZVDUUN3ME2zNU43QTN4IN88US=> NUiwRotkW0GQR1XS
SNB75 NHHCUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLYOWxOUUN3ME2zN{43PTB|IN88US=> MYXTRW5ITVJ?
KNS-42 NVTFS41CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3XTWM2OD1|NT65OlI1KM7:TR?= NEO5OI9USU6JRWK=
TUR NFvPc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN4LkC1NlEh|ryP M2XIS3NCVkeHUh?=
REH NFXMboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN5LkiyNVEh|ryP MlTsV2FPT0WU
EW-22 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P1fmlEPTB;NEKuNlg5PSEQvF2= M2THU3NCVkeHUh?=
NCI-H446 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX1TWM2OD12Mj63PFU{KM7:TR?= NUD3U|FmW0GQR1XS
ES3 M2TkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR|LkGzN|kh|ryP MV\TRW5ITVJ?
EW-11 M3K2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfh[|B{UUN3ME20OE45OjF6IN88US=> MWrTRW5ITVJ?
RH-1 NWTxUXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULWbpNTUUN3ME20O{42QDF{IN88US=> M1vSR3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals December 15 2018 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03538171 Recruiting Advanced Breast Cancer EddingPharm Oncology Co. LTD. May 15 2018 Phase 3
NCT03501381 Recruiting Renal Cell Carcinoma Roberto Pili|Indiana University Melvin and Bren Simon Cancer Center|Prometheus Laboratories|Syndax Pharmaceuticals|Hoosier Cancer Research Network May 24 2018 Phase 2
NCT02697630 Recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals February 21 2018 Phase 2
NCT03361800 Recruiting Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) January 22 2018 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×

春節(旧正月)休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は2月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID